Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients

Hepatology Research

Volumn 42, Issue 10, 2012, Pages 958-965

  Saito, Hiroaki ^a,b   Ito, Kiyoaki ^a   Sugiyama, Masaya ^a   Matsui, Teppei ^a   Aoki, Yoshihiko ^a   Imamura, Masatoshi ^a   Murata, Kazumoto ^a   Masaki, Naohiko ^a   Nomura, Hideyuki ^c   Adachi, Hiroshi ^d   Hige, Shuhei ^e   Enomoto, Nobuyuki ^f   Sakamoto, Naoya ^g   Kurosaki, Masayuki ^h   Mizokami, Masashi ^a   Watanabe, Sumio ^b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Shin Kokura Hospital   (Japan)

^d TONAMI GENERAL HOSPITAL   (Japan)

^e HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF YAMANASHI   (Japan)

^g TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^h MUSASHINO RED CROSS HOSPITAL   (Japan)

Author keywords

Aging; Genotype; IL28B; Low density lipoprotein cholesterol; Single nucleotide polymorphism

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN; INTERLEUKIN 28B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; ANTIVIRAL THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD;

EID: 84866767064     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01013.x     Document Type: Article

References (28)

1. Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20-9.
2. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 2007; 45: 806-16.
3. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
4. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
5. Hadziyannis SJ, Sette H, Jr, Morgan TR etal. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
6. Bruno S, Camma C, Di Marco V etal. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004; 41: 474-81.
7. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
8. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
9. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
10. Watanabe S, Enomoto N, Koike K etal. Cancer preventive effect of pegylated interferon alpha-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis. Hepatol Res 2011; 41: 955-64.
11. Kurosaki M, Tanaka Y, Nishida N etal. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2011; 54: 439-48.
12. Kurosaki M, Sakamoto N, Iwasaki M etal. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol 2011; 46: 401-9.
13. McHutchison JG, Manns M, Patel K etal. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
14. Ito K, Higami K, Masaki N etal. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol 2011; 49: 1853-60.
15. Lyamichev V, Mast AL, Hall JG etal. Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol 1999; 17: 292-6.
16. Lyamichev VI, Kaiser MW, Lyamicheva NE etal. Experimental and theoretical analysis of the invasive signal amplification reaction. Biochemistry 2000; 39: 9523-32.
17. Akuta N, Suzuki F, Hirakawa M etal. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421-9.
18. Rauch A, Kutalik Z, Descombes P etal. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45. 45 e1-7.
19. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C etal. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 33-7.
20. Yamada G, Iino S, Okuno T etal. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig 2008; 28: 9-16.
21. Bourliere M, Ouzan D, Rosenheim M etal. Pegylated interferon-alpha2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007). Antivir Ther 2012; 17: 101-10.
22. Karasu Z, Tekin F, Ersoz G etal. Liver fibrosis is associated with decreased peripheral platelet count in patients with chronic hepatitis B and C. Dig Dis Sci 2007; 52: 1535-9.
23. Everson GT, Hoefs JC, Seeff LB etal. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006; 44: 1675-84.
24. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008; 9: 465-76.
25. Boks MP, Derks EM, Weisenberger DJ etal. The relationship of DNA methylation with age, gender and genotype in twins and healthy controls. PLoS ONE 2009; 4: e6767.
26. Li JH, Lao XQ, Tillmann HL etal. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010; 51: 1904-11.
27. Gopal K, Johnson TC, Gopal S etal. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44: 335-40.
28. Toyoda H, Kumada T. Cholesterol and lipoprotein levels as predictors of response to interferon for hepatitis C. Ann Intern Med 2000; 133: 921.